24 May 2019 – KEI panel discussion – Assessing the implications of the development of new cell and gene-based therapies (including CAR T and CRISPR): What role should WHO play?

On Friday, 24 May 2019, Knowledge Ecology International (KEI) will convene an expert panel, “Assessing the implications of developments in cell and gene-based therapies (including CAR T and CRISPR): What role should WHO should play?” from 12h30 to 14h30 in Espace Henry Dunant at the Red Cross Museum located at Avenue de la Paix 17, Geneva. An example of the potential role the WHO secretariat could play is producing a report on potential intellectual property and regulatory barriers for cell and gene-based therapies including but not limited to CAR T and CRISPR.

Date: Friday, 24 May 2019
Time: 12h30 to 14h30
Location: Espace Henry Dunant, Red Cross Museum, Avenue de la Paix 17, Geneva

Registration is required. Please contact Thiru Balasubramaniam: thiru[at]keionline.org or Claire Cassedy: claire.cassedy[at]keionline.org to register.


Dr. Luca Li Bassi, Director General, Agenzia Italiana del Farmaco (AIFA)
Dr. Hannes Braberg, Staff Scientist, University of California, San Francisco
James Love, Director, Knowledge Ecology International (KEI)
Dr. Els Torreele, Executive Director, Médecins Sans Frontières (MSF) Access Campaign
Salome Meyer, Project Manager, Access to Medicine, Cancer Alliance
Dr. Nicola Magrini, Secretary, WHO Expert Committee on the Selection and Use of Essential Medicines, World Health Organization (WHO)

Moderator: Dr Tido von Schoen-Angerer, Board Member, KEI Europe